Pfizer Finalizes $2.3B Bextra Off-Label Marketing Deal
Pfizer Inc. will pay $2.3 billion and one of its subsidiaries will plead guilty to a criminal charge to settle claims that the drug giant improperly marketed the discontinued anti-inflammatory drug...To view the full article, register now.
Already a subscriber? Click here to view full article